Skip to main content
RNXT
NASDAQ Life Sciences

RenovoRx Appoints Experienced Public Company Executive Mark Voll as CFO

Analysis by Wiseek.ai
Sentiment info
Positive
Importance info
7
Price
$0.951
Mkt Cap
$34.85M
52W Low
$0.701
52W High
$1.5
Market data snapshot near publication time

summarizeSummary

RenovoRx appointed Mark Voll, an experienced public company executive, as its new Chief Financial Officer, while Ronald B. Kocak resigned as Principal Accounting Officer but remains Vice President and Controller.


check_boxKey Events

  • New Chief Financial Officer Appointed

    Mark Voll, an executive with over 30 years of experience in public company finance, was appointed CFO and Principal Financial and Accounting Officer, effective February 4, 2026.

  • Principal Accounting Officer Resignation

    Ronald B. Kocak resigned from his position as Principal Accounting Officer, effective February 3, 2026, but will continue to serve as Vice President and Controller.

  • Strategic Timing Amidst Nasdaq Notice

    This executive appointment follows a Nasdaq deficiency notice received on January 2, 2026, suggesting a strategic move to bolster financial leadership and investor confidence.

  • CFO Compensation Details

    Mr. Voll's compensation includes $250 per hour, paid 50% in cash and 50% in restricted stock units, with an initial grant of 60,000 unvested restricted stock units.


auto_awesomeAnalysis

The appointment of Mark Voll as Chief Financial Officer and Principal Financial and Accounting Officer is a significant positive development for RenovoRx. Mr. Voll brings over 30 years of extensive financial leadership experience, including guiding multiple public companies through IPOs and strategic exits. This expertise is particularly valuable for RenovoRx, an emerging growth company, and comes shortly after the company received a Nasdaq deficiency notice on January 2, 2026, for failing to maintain its minimum bid price. His appointment signals a strategic move to strengthen financial leadership and investor communications. Ronald B. Kocak's resignation as Principal Accounting Officer is less impactful as he retains his role as Vice President and Controller, indicating a restructuring of financial leadership rather than a complete departure.

At the time of this filing, RNXT was trading at $0.95 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $34.9M. The 52-week trading range was $0.70 to $1.50. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

descriptionView Main SEC Filing

show_chartPrice Chart

Share this article

Copied!

feed RNXT - Latest Insights

RNXT
Apr 27, 2026, 5:20 PM EDT
Filing Type: 424B3
Importance Score:
8
RNXT
Apr 16, 2026, 5:10 PM EDT
Filing Type: S-3
Importance Score:
8
RNXT
Apr 08, 2026, 8:30 AM EDT
Source: GlobeNewswire
Importance Score:
7
RNXT
Mar 30, 2026, 4:05 PM EDT
Source: GlobeNewswire
Importance Score:
8
RNXT
Mar 27, 2026, 7:00 AM EDT
Filing Type: 8-K
Importance Score:
7
RNXT
Mar 26, 2026, 8:30 AM EDT
Source: GlobeNewswire
Importance Score:
8
RNXT
Mar 24, 2026, 9:16 PM EDT
Filing Type: 4
Importance Score:
7
RNXT
Mar 24, 2026, 9:15 PM EDT
Filing Type: 4
Importance Score:
8
RNXT
Mar 23, 2026, 7:00 AM EDT
Filing Type: 8-K
Importance Score:
8
RNXT
Mar 18, 2026, 8:35 AM EDT
Source: GlobeNewswire
Importance Score:
8